The US Food and Drug Administration (FDA) has approved belzutifan (Welireg) for adults with advanced renal cell carcinoma following progression on a PD-1/L1 inhibitor and a vascular endothelial growth ...

We are excited to be developing XmAb819 as a novel first-in-class ENPP3 T-cell engager that could potentially offer a ...

Xencor's clear cell renal cell carcinoma treatment demonstrated evidence of anti-tumor activity in a phase 1 trial.

Merck Announces KEYTRUDA Plus WELIREG Met Primary Endpoint of DFS in Certain Patients With Clear Cell Renal Cell Carcinoma ...

Table 2. Modality of response/resistance to first-line VEGF/VEGFR inhibitors and possible second-line treatment options to be explored. Clinical response to first-line therapy Putative molecular ...

Select patients with oligometastatic ccRCC might be managed with a period of metastasis-directed therapy alone. Serial metastasis-directed radiation therapy may delay systemic therapy in clear cell ...

Comparison of 68Ga-NY104 PET/CT with 18F-FDG PET/CT in patients with metastatic clear cell renal cell carcinoma (NYCRM): A prospective, comparative phase II study. This is an ASCO Meeting Abstract ...

The 2025 Western Section AUA annual meeting featured a kidney cancer session and a presentation by Jaxson Jeffery discussing the impact of neoadjuvant systemic therapy on tumor and tumor thrombus ...

During a live event, Randy F. Sweis, MD, and participants discussed treating non–clear cell renal cell carcinoma based on ...

Anlotinib plus everolimus as first-line treatment for advanced non–clear cell renal cell carcinoma: 1 year updated results from UC-001, a single-center, single-arm, phase II trial. This is an ASCO ...